BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27141398)

  • 1. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.
    Otáhal P; Průková D; Král V; Fabry M; Vočková P; Latečková L; Trněný M; Klener P
    Oncoimmunology; 2016 Apr; 5(4):e1115940. PubMed ID: 27141398
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Li C; Sun Y; Wang J; Tang L; Jiang H; Guo T; Liu L; Wu Y; Ai L; Xia L; Wu J; Lin Z; Qian Q; Hu Y; Mei H
    Front Immunol; 2021; 12():599493. PubMed ID: 34113336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
    Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
    Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide improves the antitumor activity of CAR-T cells directed toward the intracellular Wilms Tumor 1 antigen.
    Zhang L; Jin G; Chen Z; Yu C; Li Y; Li Y; Chen J; Yu L
    Hematology; 2021 Dec; 26(1):818-826. PubMed ID: 34674611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo.
    Yin Y; Zhang P; He L; Guo X; Wang H; Li J; Xu Q
    Evid Based Complement Alternat Med; 2022; 2022():1227308. PubMed ID: 36034960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells.
    Štach M; Ptáčková P; Mucha M; Musil J; Klener P; Otáhal P
    Cytotherapy; 2020 Dec; 22(12):744-754. PubMed ID: 32950390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
    Fuchs O
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting.
    Rotolo A; Caputo VS; Holubova M; Baxan N; Dubois O; Chaudhry MS; Xiao X; Goudevenou K; Pitcher DS; Petevi K; Kachramanoglou C; Iles S; Naresh K; Maher J; Karadimitris A
    Cancer Cell; 2018 Oct; 34(4):596-610.e11. PubMed ID: 30300581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
    Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
    Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
    Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
    Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide.
    Works M; Soni N; Hauskins C; Sierra C; Baturevych A; Jones JC; Curtis W; Carlson P; Johnstone TG; Kugler D; Hause RJ; Jiang Y; Wimberly L; Clouser CR; Jessup HK; Sather B; Salmon RA; Ports MO
    Mol Cancer Ther; 2019 Dec; 18(12):2246-2257. PubMed ID: 31395689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
    Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
    Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
    J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties.
    Costa F; Vescovini R; Bolzoni M; Marchica V; Storti P; Toscani D; Accardi F; Notarfranchi L; Dalla Palma B; Manferdini C; Manni S; Todaro G; Lisignoli G; Piazza F; Aversa F; Giuliani N
    Oncotarget; 2017 Aug; 8(32):53053-53067. PubMed ID: 28881793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-Aptamers Enable Traceless Enrichment and Monitoring of CAR-Positive Cells and Overcome Tumor Immune Escape.
    Zhou H; Abudureheman T; Zheng WW; Yang LT; Zhu JM; Liang AB; Duan CW; Chen K
    Adv Sci (Weinh); 2024 Mar; 11(10):e2305566. PubMed ID: 38148412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
    [No Abstract]   [Full Text] [Related]  

  • 18. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
    Geyer MB; Brentjens RJ
    Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL.
    Zhou W; Miao J; Cheng Z; Wang Z; Wang J; Guo H; Wang P; Lu S; Si L; Zhang Z; Dunmall LC; Liu Y; Lemoine NR; Wang Y
    Mol Ther Oncolytics; 2023 Sep; 30():216-226. PubMed ID: 37663131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction.
    Cheng J; Mao X; Chen C; Long X; Chen L; Zhou J; Zhu L
    Cytometry A; 2023 Jan; 103(1):16-26. PubMed ID: 35875964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.